- |||||||||| ALKS 2680 / Alkermes
Evaluation of a novel, orally available orexin 2 receptor agonist, on wakefulness and cataplexy in a mouse model of Type 1 narcolepsy (Room 28) - Aug 28, 2023 - Abstract #WSS2023WSS_1132;
Activation of orexin 2 receptors via oral administration of RDC-264177 significantly improved narcolepsy-like symptomatology in orexin-DTA mice that included both decreased cataplexy and increased waking during the active phase. These preclinical data provide strong support for further investigation of RDC-264177 as a therapeutic intervention for the treatment of narcolepsy.Acknowledgements: : We wish to thank our collaborators and all past and present members of the Project Team.
- |||||||||| ALKS 2680 / Alkermes
Preliminary results from a phase 1 study of ALKS 2680, an Orexin-2 receptor agonist, in healthy participants and patients with narcolepsy or idiopathic hypersomnia (Room A06) - Aug 28, 2023 - Abstract #WSS2023WSS_470;
The orexin-2 receptor agonist ALKS 2680 is orally bioavailable and, based on preliminary data from healthy participants in a phase 1 study, appears to be centrally active and generally well-tolerated with a pharmacokinetic profile suitable for once-daily administration to promote daytime wakefulness in the treatment of narcolepsy and other disorders characterized by excessive daytime sleepiness. The effects of ALKS 2680 in patients with NT1, NT2, and IH will be evaluated, and an update of available data will be presented.Acknowledgements: This study is sponsored by Alkermes.
|
